Bausch + Lomb Posts 2024 Revenue of $4.8 Billion

Bausch + Lomb reported Feb. 19 that its 2024 revenue totaled $4.8 billion, a 16 percent increase (+17 percent cc) over $4.1 billion in 2023.

The company’s Q4-2024 revenue was $1.3 billion, a 9 percent increase (+11 percent cc) over $1.2 billion in Q4-2023.

Surgical segment revenue for 2024 was $843 million, a 10 percent increase (+11 percent cc) over $767 million in 2023. Within the segment, consumables produced $431 million; equipment, $209 million; and implantables, $203 million.

Q4-2024 surgical segment revenue was $231 million, a 13 percent increase (+15 percent cc) over $204 million in Q4-2023. Consumables accounted for $114 million; equipment, $61 million; and implantables, $56 million.

The company said the increase during both time periods was due in part to strong growth in its premium IOL portfolio.

Ophthalmic pharmaceutical revenue in 2024 was $1.2 billion, a 45 percent increase over $836 million in 2023, primarily due to incremental sales of Xiidra, the launch of Miebo, and growth in the company’s US generics and international pharmaceuticals segments.

Ophthalmic pharma revenue in Q4-2024 was $326 million, a 6 percent increase (+7 percent cc) over $307 million in Q4-2023, primarily driven by strong execution of the launch of Miebo.

The vision care segment in 2024 accounted for $2.7 billion, an 8 percent increase (+10 percent cc) over $2.5 billion in 2023.

Q4-2024 vision care revenue was $723 million, a 9 percent increase (+11 percent cc) over $662 million in Q4-2023. Factors driving growth in both time periods were increased demand for Lumify, over-the-counter dry eye products, and eye vitamins in the consumer business, plus Daily SiHy lenses and Bausch + Lomb Ultra in the contact lens business.

Bausch + Lomb provided 2025 revenue guidance of $4.95 billion to $5.05 billion, for growth in constant currency of about 5.5 to 7.5 percent.

The company is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey.